← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Siamab Therapeutics, Inc.
Newton, MA
$3,096,095
Total funding
6
Grants
Funding over time
peak $1.5M · FY2008–16$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$3,096,095 · 6
By mechanism
N44$2,299,288 · 2
R43$372,372 · 2
N43$222,319 · 1
R41$202,116 · 1
Investigators at Siamab Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
IGF::OT::IGF: SBIR PHASE II, TOPIC 326: DEVELOPMENT OF NOVEL THERAPEUTIC AGENTS THAT TARGET CANCER STEM CELLS$1,499,399
N44 · FY2016 · CA
THE PURPOSE OF THIS TOPIC IS TO DEVELOP TECHNOLOGIES TO CHARACTERIZE GLYCAN MOIE$799,889
N44 · FY2009 · CA
SPECIFIC GLYCAN TARGETING TO ERADICATE CANCER STEM CELLS$222,319
N43 · FY2014 · CA
Lead identification of therapeutic anti-glycan antibodies for cancer therapy$219,846
R43 · FY2015 · CA
Detection of Non-Human Sialic Acid in Biotherapeutic Applications$167,772
R41 · FY2008 · GM
N-glycolylneuraminic Acid in the Pathogenesis and Progression of Rheumatoid Arthr$152,526
R43 · FY2009 · AR
Detection of Non-Human Sialic Acid in Biotherapeutic Applications$34,344
R41 · FY2009 · GM